Unichem Laboratories Limited (UNICHEMLAB) Share Price

NSE · Healthcare · Drug Manufacturers - Specialty & Generic · ISIN INE351A01035

₹566.75+10.40 (+1.87%)

Key metrics

Market Cap
₹3,917 Cr
P/E Ratio
12.87
EPS
43.24
Book Value
385.97
P/B Ratio
1.45
ROE
9.3%
ROCE
1.98%
Debt / Equity
0.18
Net Margin
11.71%
Revenue Growth
4.6%
Profit Growth
83.86%
Dividend Yield
52W High
₹687.20
52W Low
₹278.20
Market Cap Band
small cap
Face Value
2

Ratios computed from the annual results period ending 2026-03-31.

About Unichem Laboratories Limited

Unichem Laboratories Limited, a pharmaceutical company, manufactures and sells pharmaceutical products in Asia, Europe, Africa, CIS, the United States, and internationally. The company offers formulation products that address various therapeutic areas, such as gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infective, and pain management. It also offers active pharmaceutical ingredients, as well as contract manufacturing services. In addition, the company manufactures allopathic medicines, formulations, bulk drugs, and chemicals. It serves distributors, health care professionals, and government institutions. The company was founded in 1944 and is based in Mumbai, India. Unichem Laboratories Limited is a subsidiary of Ipca Laboratories Limited.

Headquarters
Mumbai, India
Employees
2,780
Promoter Holding
71.26%

The full Unichem Laboratories Limited analysis

Create a free account to open the complete UNICHEMLAB deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.

  • 10-year financialsIncome statement, balance sheet and cash flow, year by year.
  • Valuation & fair valueFair-value estimates, quality scores and a value grade.
  • Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
  • Shareholding historyPromoter, FII, DII and public holdings across every quarter.
  • Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
  • Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.